PMID- 27382546
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160706
LR  - 20201001
IS  - 2251-6581 (Print)
IS  - 2251-6581 (Electronic)
IS  - 2251-6581 (Linking)
VI  - 15
DP  - 2015
TI  - Effects of vildagliptin as add-on treatment in patients with type 2 diabetes 
      mellitus: insights from long-term clinical studies in Japan.
PG  - 21
LID - 10.1186/s40200-016-0240-z [doi]
LID - 21
AB  - BACKGROUND: Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is wildly 
      used to treat type 2 diabetes mellitus (T2DM) with mono- or combination-therapy. 
      We review two previously published open-label studies to extract insights on the 
      long-term efficacy and safety of vildagliptin. METHODS: Two studies were 
      conducted in Japan to assess the efficacy and safety of vildagliptin as an add-on 
      to other oral antidiabetes drugs (OADs) for 52 weeks. These studies were 
      performed under the similar protocol in Japanese patients with T2DM who were 
      inadequately controlled with OAD monotherapy [excluding other dipeptidyl 
      peptidase-4 (DPP-4) inhibitors]. RESULTS: Addition of vildagliptin (50 mg twice 
      daily) to other OAD monotherapy [sulfonylurea (SU), metformin, thiazolidinedione, 
      alpha-glucosidase inhibitor and glinide] reduced glycated hemoglobin (HbA1c) 
      levels by -0.64 %,-0.75 %,-0.92 %,-0.94 % and - 0.64 %, respectively, over 
      52 weeks of treatment. Overall, the incidence of hypoglycemia was low and was 
      slightly higher in the add-on to SU treatment group compared with the other 
      groups. The incidences of adverse events were comparable among the treatment 
      groups, and vildagliptin was well-tolerated as add-on therapy to other OADs. 
      CONCLUSIONS: The evidence from the two studies indicates that vildagliptin as an 
      add-on therapy to other OADs is a clinically reasonable option for Japanese 
      patients with T2DM who respond inadequately to other OAD monotherapy.
FAU - Odawara, Masato
AU  - Odawara M
AD  - The Department of Diabetology, Endocrinology, Metabolism and Rheumatology, Tokyo 
      Medical University, 6-7-1, Nishi-Shinjuku, Shinjuku-ku, Tokyo 160-0023 Japan.
FAU - Sagara, Rieko
AU  - Sagara R
AD  - Medical Division, Novartis Pharm K.K, Toranomon Hills Mori Tower, 23-1, Toranomon 
      1-chome, Minato-ku, 105-6333 Tokyo Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160704
PL  - Switzerland
TA  - J Diabetes Metab Disord
JT  - Journal of diabetes and metabolic disorders
JID - 101590741
PMC - PMC4932694
OTO - NOTNLM
OT  - Combination therapy
OT  - Dipeptidyl peptidase-4 inhibitor
OT  - Long-term administration
OT  - Oral antidiabetes drugs
OT  - Vildagliptin
EDAT- 2015/01/01 00:00
MHDA- 2015/01/01 00:01
PMCR- 2016/07/04
CRDT- 2016/07/07 06:00
PHST- 2016/03/03 00:00 [received]
PHST- 2016/06/12 00:00 [accepted]
PHST- 2016/07/07 06:00 [entrez]
PHST- 2015/01/01 00:00 [pubmed]
PHST- 2015/01/01 00:01 [medline]
PHST- 2016/07/04 00:00 [pmc-release]
AID - 240 [pii]
AID - 10.1186/s40200-016-0240-z [doi]
PST - epublish
SO  - J Diabetes Metab Disord. 2016 Jul 4;15:21. doi: 10.1186/s40200-016-0240-z. 
      eCollection 2015.